Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-5948 in relapsed/refractory B-cell malignancies
NL-OMON59960Phase 1Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Oct 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of bexobrutideg in B-cell malignancy, sponsored by Nurix Therapeutics. Primary endpoint: Primary endpoint(s). Started Oct 2023; status: recruiting.
02
Drugs
bexobrutideg
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NL-OMON59960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59960.